Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 1 | $0 |
Sells | 19 | $3,208,902 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
08 Jul 2024 16:30 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 24 Jun 2024 | Sale | 6,849 | 2.12 | 14,520 | D |
07 Jun 2024 21:40 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 29 May 2024 | Purchase | 2,500 | 0 | 0 | D |
18 Dec 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Dec 2023 | Sale | 5,803 | 14.1763 | 82,265 | D |
18 Dec 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Dec 2023 | Sale | 26,732 | 12.9401 | 345,915 | D |
08 Dec 2023 17:57 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 07 Dec 2023 | Sale | 36,800 | 11.8477 | 435,995 | D |
22 Nov 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 21 Nov 2023 | Sale | 18,665 | 10.2628 | 191,555 | D |
21 Nov 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 20 Nov 2023 | Sale | 14,594 | 11.2554 | 164,261 | D |
21 Nov 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 17 Nov 2023 | Sale | 3,541 | 13.0386 | 46,170 | D |
25 Oct 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 24 Oct 2023 | Sale | 5,200 | 19.106 | 99,351 | D |
11 Oct 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 10 Oct 2023 | Sale | 400 | 22.906 | 9,162 | D |
11 Oct 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 10 Oct 2023 | Sale | 4,800 | 21.9374 | 105,300 | D |
27 Sep 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 26 Sep 2023 | Sale | 2,203 | 24.4623 | 53,890 | D |
27 Sep 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 26 Sep 2023 | Sale | 1,114 | 23.5145 | 26,195 | D |
27 Sep 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 26 Sep 2023 | Sale | 1,883 | 22.5397 | 42,442 | D |
21 Sep 2023 16:35 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 20 Sep 2023 | Sale | 6,000 | 27.9643 | 167,786 | D |
18 Sep 2023 20:13 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Sep 2023 | Sale | 4,675 | 22.2913 | 104,212 | D |
18 Sep 2023 20:13 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Sep 2023 | Sale | 5,725 | 21.5578 | 123,418 | D |
15 Sep 2023 20:06 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 13 Sep 2023 | Sale | 29,800 | 21.1385 | 629,927 | D |
30 Aug 2023 19:22 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 30 Aug 2023 | Sale | 19,800 | 24.7 | 489,060 | D |
22 Aug 2023 16:14 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 18 Aug 2023 | Sale | 3,265 | 23.73 | 77,478 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)